

ASEAN Infusion Pump - Company Evaluation Report, 2025

Market Report | 2025-08-01 | 149 pages | MarketsandMarkets

AVAILABLE LICENSES:

- Single User \$2650.00
- Corporate License \$4250.00

Report description:

The ASEAN Infusion Pump Companies Quadrant is a comprehensive industry analysis that provides valuable insights into the global market for ASEAN Infusion Pump. This quadrant offers a detailed evaluation of key market players, technological advancements, product innovations, and emerging trends shaping the industry. MarketsandMarkets 360 Quadrants evaluated over 140 companies, of which the Top 15 ASEAN Infusion Pump Companies were categorized and recognized as quadrant leaders. The ASEAN infusion pumps market is experiencing significant growth, driven by the rising burden of chronic diseases, expanding healthcare infrastructure, and increasing demand for advanced drug delivery systems. As conditions such as cancer, diabetes, and renal failure become more prevalent across Southeast Asia, hospitals and clinics are increasingly adopting infusion pumps to ensure precise and controlled medication delivery. Countries like Indonesia, Vietnam, Thailand, and the Philippines are rapidly modernizing their healthcare systems, with substantial investments in hospital equipment and critical care technologies further supporting market expansion.

A major growth factor is the region's aging population, which is more susceptible to chronic illnesses requiring long-term intravenous therapies. This demographic shift is fueling consistent demand for infusion pumps in both hospital and homecare settings. In parallel, governments across the ASEAN region are prioritizing healthcare system improvements, leading to increased public and private investments in medical technologies, including infusion systems. Additionally, the availability of cost-effective, locally manufactured infusion devices is making advanced care more affordable and accessible in price-sensitive markets, promoting broader adoption in both urban and rural healthcare facilities.

The 360 Quadrant maps the ASEAN Infusion Pump companies based on criteria such as revenue, geographic presence, growth strategies, investments, and sales strategies for the market presence of the ASEAN Infusion Pump quadrant. The top criteria for product footprint evaluation included By Product (Accessories and Consumables, Devices), By Application (Chemotherapy/Oncology, Diabetes Management, Gastroenterology, Analgesia/Pain Management, Analgesia/Pain Management, Hematology, Other Applications), and By End User (Hospitals, Home Care Settings, Ambulatory Care Settings, Academic & Research Institutes).

Key Players

Key players in the ASEAN Infusion Pump market include major global corporations and specialized innovators such as Becton, Dickinson and Company (US), B. Braun Melsungen AG (Germany), Baxter International (US), Fresenius Kabi (Germany), Terumo Corporation (Japan), ICU Medical, Inc. (US), Roche Diagnostics (Switzerland), Nipro (Japan), Cardinal Health, Inc. (US), Abbott Laboratories (US), Danaher Corporation (US), Medtronic plc (Ireland), Ypsomed Holding AG (Switzerland), JMS Co., Ltd. (Japan), and

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Avanos Medical, Inc. (US). These companies are actively investing in research and development, forming strategic partnerships, and engaging in collaborative initiatives to drive innovation, expand their global footprint, and maintain a competitive edge in this rapidly evolving market.

Top 3 Companies

Becton, Dickinson and Company

Becton, Dickinson and Company—commonly known as BD—is a global medical technology company that develops, manufactures, and sells medical devices, instrument systems, and reagents for healthcare institutions, life science researchers, clinical laboratories, and the pharmaceutical industry. The company operates through three main business segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment, operations are further divided into four business units: Medication Delivery Solutions, Medication Management Solutions, Pharmaceutical Systems, and Diabetes Care.

Fresenius Kabi

Fresenius Kabi, a wholly owned subsidiary of Fresenius SE & Co. KGaA, is a global healthcare company specializing in products and services for dialysis, hospital care, and outpatient medical treatment. The company operates through four primary business segments: Medtech, Nutrition, Biopharmaceuticals, and Pharma Business. Through its Medtech segment, Fresenius Kabi offers a comprehensive range of infusion pumps and related accessories, supporting safe and efficient drug delivery in clinical settings.

Terumo Corporation

Terumo Corporation develops and manufactures a wide range of medical products and equipment, including pharmaceuticals, nutritional supplements, blood bags, disposable medical devices, cardiovascular systems, vascular grafts, peritoneal dialysis solutions, blood glucose monitoring systems, and digital thermometers. The company operates through three main business segments: Cardiac and Vascular, General Hospital Company, and Blood & Cell Technologies.

Table of Contents:

1	INTRODUCTION	13
1.1	MARKET DEFINITION	13
1.2	INCLUSIONS AND EXCLUSIONS	13
1.3	STAKEHOLDERS	14
2	EXECUTIVE SUMMARY	15
3	MARKET OVERVIEW	19
3.1	MARKET DYNAMICS	19
3.1.1	MARKET DRIVERS	20
3.1.1.1	Rising demand for ambulatory infusion pumps in home care settings	20
3.1.1.2	Rapid growth in geriatric population and subsequent rise in chronic diseases	20
3.1.1.3	Increased adoption of enteral feeding pumps due to surge in pre-term births	22
3.1.1.4	Growing number of surgical procedures performed worldwide	23
3.1.1.5	Increased safety & cybersecurity requirements	23
3.1.2	RESTRAINTS	24
3.1.2.1	Product recalls	24
3.1.2.2	Stringent regulatory requirements for new product approvals	24
3.1.2.3	Increasing adoption of refurbished & rented infusion pumps	25
3.1.3	OPPORTUNITIES	25
3.1.3.1	High growth of emerging economies	25
3.1.3.2	Growing popularity of specialty infusion systems	26
3.1.4	CHALLENGES	26
3.1.4.1	Increasing incidence of medication errors and inadequate wireless connectivity in most hospitals	26

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

3.2	INDUSTRY TRENDS	27
3.2.1	SMART PUMP-EMR INTEROPERABILITY	27
3.2.2	DEVELOPMENT OF HYBRID CLOSED-LOOP SYSTEMS/ARTIFICIAL PANCREAS DEVICE SYSTEMS	28
3.2.3	GROWING DEMAND FOR SPECIALTY PUMPS WITH ADVANCED FEATURES	30
3.3	TECHNOLOGY ANALYSIS	30
3.3.1	KEY TECHNOLOGIES	30
3.3.1.1	Flow generation	30
3.3.1.2	Smart infusion systems	31
3.3.1.3	Closed-loop infusion control	31
3.3.2	COMPLEMENTARY TECHNOLOGIES	32
3.3.2.1	Dose error reduction systems	32
3.3.2.2	Wireless connectivity	33
3.3.2.3	AI-powered decision support systems	33
3.3.3	ADJACENT TECHNOLOGIES	34
3.3.3.1	Embedded software	34
3.3.3.2	Sensing technology	34
3.4	PORTER'S FIVE FORCES ANALYSIS	35
3.4.1	THREAT OF NEW ENTRANTS	35
3.4.2	THREAT OF SUBSTITUTES	36
3.4.3	BARGAINING POWER OF SUPPLIERS	36
3.4.4	BARGAINING POWER OF BUYERS	36
3.4.5	INTENSITY OF COMPETITIVE RIVALRY	36
3.5	PATENT ANALYSIS	37
3.5.1	PATENT PUBLICATION TRENDS FOR INFUSION PUMPS	37
3.5.2	INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS	38
3.6	KEY CONFERENCES AND EVENTS, 2025-2026	39
3.7	IMPACT OF AI ON ASEAN INFUSION PUMPS MARKET	40
3.7.1	INTRODUCTION	40
3.7.2	MARKET POTENTIAL IN ASEAN INFUSION PUMPS ECOSYSTEM	40
3.7.3	AI USE CASES	41
3.7.4	KEY COMPANIES IMPLEMENTING AI IN INFUSION PUMPS	41
3.7.5	FUTURE OF GEN AI IN ASEAN INFUSION PUMPS ECOSYSTEM	42
3.8	ECOSYSTEM ANALYSIS	42
3.9	VALUE CHAIN ANALYSIS	44
4	COMPETITIVE LANDSCAPE	46
4.1	OVERVIEW	46
4.2	KEY PLAYER STRATEGIES/RIGHT TO WIN, 2022-2025	46
4.3	REVENUE ANALYSIS, 2020-2024	48
4.4	MARKET SHARE ANALYSIS, 2024	49
4.5	COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024	51
4.5.1	STARS	51
4.5.2	EMERGING LEADERS	51
4.5.3	PERVASIVE PLAYERS	51
4.5.4	PARTICIPANTS	51
4.5.5	COMPANY FOOTPRINT: KEY PLAYERS, 2024	52
4.5.5.1	Company footprint	52
4.5.5.2	Product footprint	54

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

4.5.5.3	Application footprint	55
4.5.5.4	End user footprint	56
4.6	COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024	56
4.6.1	PROGRESSIVE COMPANIES	56
4.6.2	RESPONSIVE COMPANIES	57
4.6.3	DYNAMIC COMPANIES	57
4.6.4	STARTING BLOCKS	57
4.6.5	COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024	58
4.6.5.1	Detailed list of key startups/SMEs	58
4.6.5.2	Competitive benchmarking of key startups/SMEs	58
4.7	R&D EXPENDITURE OF KEY PLAYERS	59
4.8	COMPANY VALUATION AND FINANCIAL METRICS	59
4.8.1	COMPANY VALUATION	59
4.8.2	FINANCIAL METRICS	60
4.9	BRAND/PRODUCT COMPARISON	61
4.10	COMPETITIVE SCENARIO	62
4.10.1	PRODUCT LAUNCHES & APPROVALS	62
4.10.2	DEALS	65
4.10.3	EXPANSIONS	67
4.10.4	OTHER DEVELOPMENTS	68
5	COMPANY PROFILES	70
5.1	KEY PLAYERS	70
5.1.1	BECTON, DICKINSON AND COMPANY	70
5.1.1.1	Business overview	70
5.1.1.2	Products offered	71
5.1.1.3	Recent developments	74
5.1.1.3.1	Product launches & approvals	74
5.1.1.3.2	Deals	74
5.1.1.3.3	Expansions	75
5.1.1.3.4	Other developments	75
5.1.1.4	MnM view	76
5.1.1.4.1	Right to win	76
5.1.1.4.2	Strategic choices	76
5.1.1.4.3	Weaknesses and competitive threats	76
5.1.2	B. BRAUN MELSUNGEN AG	77
5.1.2.1	Business overview	77
5.1.2.2	Products offered	78
5.1.2.3	Recent developments	83
5.1.2.3.1	Product launches & approvals	83
5.1.2.3.2	Deals	84
5.1.2.3.3	Other developments	84
5.1.2.4	MnM view	84
5.1.2.4.1	Right to win	84
5.1.2.4.2	Strategic choices	85
5.1.2.4.3	Weaknesses and competitive threats	85
5.1.3	BAXTER INTERNATIONAL INC.	86
5.1.3.1	Business overview	86

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

5.1.3.2	Products offered	87
5.1.3.3	Recent developments	89
5.1.3.3.1	Product launches & approvals	89
5.1.3.3.2	Deals	89
5.1.3.3.3	Other developments	89
5.1.3.4	MnM view	90
5.1.3.4.1	Right to win	90
5.1.3.4.2	Strategic choices	90
5.1.3.4.3	Weaknesses and competitive threats	90
5.1.4	FRESENIUS KABI	91
5.1.4.1	Business overview	91
5.1.4.2	Products offered	92
5.1.4.3	Recent developments	95
5.1.4.3.1	Product launches & approvals	95
5.1.4.3.2	Deals	95
5.1.4.3.3	Other developments	96
5.1.4.4	MnM view	96
5.1.4.4.1	Right to win	96
5.1.4.4.2	Strategic choices	96
5.1.4.4.3	Weaknesses and competitive threats	96
5.1.5	MEDTRONIC PLC	97
5.1.5.1	Business overview	97
5.1.5.2	Products offered	98
5.1.5.3	Recent developments	99
5.1.5.3.1	Product launches & approvals	99
5.1.5.3.2	Deals	100
5.1.5.4	MnM view	100
5.1.5.4.1	Right to win	100
5.1.5.4.2	Strategic choices	100
5.1.5.4.3	Weaknesses and competitive threats	101
5.1.6	TERUMO CORPORATION	102
5.1.6.1	Business overview	102
5.1.6.2	Products offered	103
5.1.6.3	Recent developments	104
5.1.6.3.1	Product launches & approvals	104
5.1.6.3.2	Expansions	105
5.1.6.3.3	Deals	105
5.1.7	ICU MEDICAL, INC.	106
5.1.7.1	Business overview	106
5.1.7.2	Products offered	107
5.1.7.3	Recent developments	108
5.1.7.3.1	Product launches & approvals	108
5.1.7.3.2	Deals	109
5.1.7.3.3	Other developments	109
5.1.8	AVANOS MEDICAL, INC.	110
5.1.8.1	Business overview	110
5.1.8.2	Products offered	111

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

5.1.9	NIPRO CORPORATION	113
5.1.9.1	Business overview	113
5.1.9.2	Products offered	114
5.1.9.3	Recent developments	115
5.1.9.3.1	Expansions	115
5.1.10	MS CO., LTD.	117
5.1.10.1	Business overview	117
5.1.10.2	Products offered	118
5.1.11	CARDINAL HEALTH, INC.	120
5.1.11.1	Business overview	120
5.1.11.2	Products offered	121
5.1.12	ROCHE DIAGNOSTICS	123
5.1.12.1	Business overview	123
5.1.12.2	Products offered	124
5.1.12.3	Recent developments	125
5.1.12.3.1	Expansions	125
5.1.13	ABBOTT LABORATORIES	126
5.1.13.1	Business overview	126
5.1.13.2	Products offered	127
5.1.14	DANAHER CORPORATION	128
5.1.14.1	Business overview	128
5.1.14.2	Products offered	129
5.1.15	YPSOMED HOLDING AG	131
5.1.15.1	Business overview	131
5.1.15.2	Products offered	132
5.2	OTHER PLAYERS	133
5.2.1	SOOIL DEVELOPMENTS CO., LTD.	133
5.2.2	EPIC MEDICAL	134
5.2.3	MINDRAY MEDICAL INTERNATIONAL LIMITED	135
5.2.4	BIONET CO., LTD.	136
5.2.5	TANDEM DIABETES CARE, INC.	137
5.2.6	SHENZHEN MEDRENA BIOTECH CO., LTD.	138
5.2.7	ALLIED MEDICAL LIMITED	139
5.2.8	BPL MEDICAL TECHNOLOGIES	140
5.2.9	NAREENA LIFESCIENCES PRIVATE LIMITED	141
5.2.10	HARVARD BIOSCIENCE INC.	142
6	APPENDIX	143
6.1	RESEARCH METHODOLOGY	143
6.1.1	RESEARCH APPROACH	143
6.1.1.1	Secondary data	144
6.1.1.2	Primary data	144
6.1.2	RESEARCH ASSUMPTIONS	145
6.2	COMPANY EVALUATION MATRIX: METHODOLOGY	146
6.3	AUTHOR DETAILS	149

ASEAN Infusion Pump - Company Evaluation Report, 2025

Market Report | 2025-08-01 | 149 pages | MarketsandMarkets

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User	\$2650.00
	Corporate License	\$4250.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2026-02-09"/>
		Signature	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com